新功能、新界面、新体验,扫描即可下载生物谷APP!
首页 » 礼来 » 诺和诺德、赛诺菲、礼来主导美国120亿美元糖尿病市场

诺和诺德、赛诺菲、礼来主导美国120亿美元糖尿病市场

来源:生物谷 2013-07-15 16:48

2013年7月15日讯 /生物谷BIOON/ --美国市场调研公司iData Research发布最新报告称,在美国糖尿病监测、治疗、药物递送达120亿美元的市场中,诺和诺德(Novo Nordisk)、赛诺菲(Sanofi)、礼来(Eli Lilly)3者占统治地位。

据美国糖尿病协会(American Diabetes Association)的最新统计数据,2011年在美国有超过2500万儿童和成人糖尿病患者。此外,据估计将有7900万人处于“糖尿病前期(prediabetic)”。

处于“糖尿病前期”的群体,发展成为糖尿病及糖尿病并发症的风险大大增加。这类群体,若积极采取行动来更好地管理血糖水平,有望推迟或预防糖尿病的发生。目前,糖尿病为美国疾病致死第七大疾病,同时也是其他疾病如心脏病、中风、失明、截肢、肾衰竭的积极刺激因素。

据iData Research的最新情报,目前糖尿病监测、诊断、治疗、药物递送市场价值近120亿美元。由于在I型和II型糖尿病治疗中的成功,胰岛素占据着该市场的最大份额。该市场预计将保持强劲增长,同时将受糖尿病、肥胖及新的药物递送模式如胰岛素笔、胰岛素泵、胰岛素贴等因素刺激。仅胰岛素笔单元,预计将以2位数的速度增长,因为新诊糖尿病患者更好地了解了胰岛素笔的便利性。占主导地位的胰岛素笔制造商正在营销、宣传后盾等方面投入巨资,被证明是一个非常强大的市场驱动力。

基于在美国胰岛素产品及胰岛素笔市场中的强大存在,诺和诺德依旧是该市场的领导者,利用其胰岛素产品NovoLog(R)、Novolin(R)及胰岛素笔FlexPen(R)、NovoPen(R)、NovoLet攫取了市场总量的近1/4。赛诺菲和礼来则分别占据市场的第2和第3位置,与诺和诺德在胰岛素和胰岛素笔市场正展开激烈的竞争。

Lifescan和罗氏诊断(Roche Diagnostics)也是重量级选手,主要占据糖尿病诊断环节。Lifescan积极融入糖尿病社区,通过改善患者的教育和开发新的药物、配套法例、医疗改革来改善患者的生活质量。罗氏诊断则专注于具创新和前瞻性的医疗解决方案。它们全面的产品组合包括为参考实验室、医院实验室、血库、专业测试机构提供的产品。(生物谷Bioon.com)

英文原文:Novo Nordisk, Sanofi, and Eli Lilly Lead in the $12 Billion U.S. Diabetes Monitoring, Treatment, and Drug Delivery Market, Reports iData Research Inc.
July 15, 2013, 3:05 a.m. EDT As diabetes rates reach alarming rates in the United States, affecting close to 10% of the total population, the market for diagnostics and treatment of the illness grows.

VANCOUVER, Canada, Jul 15, 2013 (GLOBE NEWSWIRE via COMTEX) -- via PRWEB - According to the latest statistics recorded by the American Diabetes Association, over 25 million children and adults in the United States were suffering from diabetes in 2011. Moreover, it is estimated that there are 79 million people who are prediabetic. People with prediabetes have an increased risk of becoming diabetic and are susceptible to the complications associated with the disease. However, if patients take action to better manage their blood glucose, they can delay or prevent diabetes from developing. The illness is the seventh leading cause of death in the U.S. and contributes to other maladies such as heart disease, stroke, blindness, amputations, and kidney failure.

According to the latest intelligence from iData Research, the market for diabetes monitoring, diagnosis, treatment, and drug delivery is valued at nearly $12 billion. With its success in treating both type 1 and type 2 diabetes, insulin represents the largest portion of the market. "This market is expected to maintain strong growth, and will be spurred by factors such as the number of diabetics, obesities, and alternative modes of delivery, such as insulin pens, pumps, and patches," explains Dr. Kamran Zamanian, CEO of iData Research. "Units of insulin pens, for example, are expected to grow at double-digit rates, as newly diagnosed diabetics who are prescribed insulin are better informed of the conveniences of an insulin pen." The dominant pen manufacturers are investing heavily in marketing, and the promotional backing is proving to be a very strong market driver.

Due to its great presence in both the insulin and insulin pen market in the U.S., Novo Nordisk is the market leader, dominating close to a quarter of the total market with products such as the NovoLog(R) and Novolin(R)R insulin products, and FlexPen(R), NovoPen(R), and NovoLet(R) insulin pens. Sanofi and Eli Lilly occupy the second and third places in the total market, respectively, competing with Novo Nordisk in the insulin and insulin pen markets. Lifescan and Roche Diagnostics are also large players, working primarily in the diabetes diagnostics sector. Lifescan is very involved in the diabetes community and is working to improve patient education and patient quality of life through development of new drugs, supporting legislation and healthcare reform to benefit people with diabetes. Roche Diagnostics is focused on innovation and forward-thinking solutions for healthcare. Their comprehensive portfolio includes products for reference labs, hospital labs, blood banks and specialty testing.

The global series on the Markets for Diabetes Monitoring, Treatment, and Drug Delivery covering the U.S. and 15 counties in Europe is available here. The full reports provide a comprehensive analysis including procedure numbers, units sold, market value, forecasts, as well as a detailed competitive market shares and analysis of major players' success strategies in each market and segment. The reports also cover markets for: traditional blood glucose meters, continuous glucose monitoring, blood glucose test strips, lancet and lancing devices, insulin, insulin syringes, insulin pens, insulin pumps, as well as emerging markets and alternative therapies.

About iData Research

iData Research is an international market research and consulting group focused on providing market intelligence for medical device and pharmaceutical companies. iData covers research in: diabetes, cardiac surgery, vascular access, infusion therapy, cardiac rhythm management, patient monitoring, and electronic medical records.

温馨提示:87%用户都在生物谷APP上阅读,扫描立刻下载! 天天精彩!


相关标签

最新会议 培训班 期刊库